Comparative study to evaluate safety and efficacy of Metformin versus sitagliptin alone and combination in type 2 diabetes mellitus

Pravin G. Dhone; Desabandhu Behera; Nilesh Gundawar; Mohd. Faheem Mubeen

doi:10.53730/ijhs.v6nS5.10038

Authors

Pravin G. Dhone Professor & Head, Department of Pharmacology, RSDKS GMC, Ambikapur
Desabandhu Behera Department of Medicine Bhima Bhoi medical college, Balangir
Nilesh Gundawar Specialist PICU Al Jalila Children’s Hospital Dubai
Mohd. Faheem Mubeen Associate Professor, Department of Pharmacology, Ayaan Institute Of Medical Science Hyderabad

Keywords:

Sitagliptin, Metformin, Hyperglycaemia

Abstract

Type 2 Diabetes mellitus (Type 2DM) is chronic, lifelong progressive metabolic disease characterized by hyperglycaemia due to absolute or relative insulinopaenia. The metabolic dysregulation that contributes to hyperglycaemia includes diminished insulin secretion, impaired glucose utilization or increased glucose production, and eventually causes pathophysiological changes in multiple organs and organ systems. Our study showed Sitagliptin was superior in reducing HOMA-IR when compared with metformin. If combination of Sitagliptin and metformin is used far superior reduction will be achieved on HOMA- IR. Limitation of our study was short duration of study and small sample size.

Downloads

Download data is not yet available.

References

World Health Organization, World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia; report of a WHO/IDF consultation. Geneva: World Health Organization. 2006 :1-50.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 (1): 81-90.

World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization. 2006.

International Diabetes Federation (IDF). IDF diabetes atlas. 4th ed. Brussels: IDF Executive Office. 2010.

Anjana RM, Pradeepa R, Deepa M et al. The Indian Council of Medical Research—India Diabetes (ICMR—INDIAB) Study: methodological details. J Diabetes Sci Technol. 2011; 5:906-14.

International Diabetes Federation. IDF Diabetes Atlas, 6th ed. Brussels, Belgium: International Diabetes Federation. 2013.

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet.2009;374:1677-86.

Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30:753-9

Bonora E, KLiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et aL Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 1998; 47: 1643-9.

Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep 2009; 9:193-9.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412- 9.

Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009; 55:363-9.

Smith U. Sitagliptin: mechanism of action. Int J Clin Pract Suppl. 2001 ;(121):13-8.

Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992; 340:925-9.

Martens FMAC, Visseren FLJ, Lemay J, de Koning EJP, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinedione’s. Drugs. 2002; 62:1463-80.

MP van der et al, MAJ Elstl, EMW van de Garde2, EGAH van MiI3, CAJ Knibbe2 and MMJ van der Vorst Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo controlled trial. Nutrition & Diabetes. 2016; 6:228-41.

Silvio I, Inzucchi J, Catherine M, Viscoli J, Lawrence II Young. Kernan. for the IRIS Trial Investigators. Sitagliptin Prevents Diabetes in Patients with Insulin Resistance and Cerebrovascular Disease Diabetes Care 2016; 39:1684-92.

Imre P, Gyo RG, Jermendy, Effect of Sitagliptin Compared with Metformin in on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with type 2 Diabetes. Journal of Clinical endocrinology Metabolism 88(4): 1637 1645.

Goldstein BJ. Cinglos MN. Luieeford JK, Johnson J, Williams- Merman. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;3: 1979-87.

Aronoff S, Rosenblatt S, Braithw Jite, Egan JW, Mathisen AL, Schneider K. Sitagliptin hydrotherapy monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6- month randomized placebo- controlled dose-response study. The Sitagliptin 001 Study Group Diabetes. 2000;23(11): 1605-11.

Chu NY, Kong AP, Kim DD, Armstrong IX Baxi S, Deutsch R. Caulfield M. Mudaliar SR. Reitz R, Henry RR, Reaven PD. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. 2002; 25:542-9.

Herman, H., Ardani, I. G. A. I., Aryani, L. N. A., Windiani, I. G. A. T., Adnyana, I. G. N. S., & Setiawati, Y. (2022). Signs and symptoms of depression in children and adolescents with type 1 diabetes mellitus: A case report. International Journal of Health & Medical Sciences, 5(1), 150-153. https://doi.org/10.21744/ijhms.v5n1.1861

Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338:867-72.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Halisten K, Virtanen KA, Lo'nnqvist F, Sipila H, Oksanen A, Viljanen T. Rosiglitazone but not metformin enhances insulin- and exercise- stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002; 51:3479-85.

Bajaj M, Suraamomkul S, Pratipanawatr T, Hardies L, Glass L, Miyaziki Y, Pratipanawatr W, Cersosimo E, DeFronzo R. Effect of Sitagliptin on splanchnic glucose uptake, endogenous glucose production, and hepatic fat content in type 2 diabetes mellitus (T2DM). Diabetes. 2002; 51(2):35.

Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999; 22:908-12.

Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001 86:4615-7.

Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23:57-63.